Cabozantinib promotes survival in HCC for both ALBI subgroups

October 20, 2021|Federal Practitioner

Clinical Edge Journal Scan: HCC November 2021 (1 of 11)

Key clinical point: Cabozatinib significantly improved overall survival and progression-free survival in HCC patients with ALBI grades 1 and 2 compared with placebo.

Major finding: Median overall survival in HCC patients with ALBI grade 1 was 17.5 months for in the cabozantinib group vs 11.4 months in the placebo group; median overall survival in patients with ALBI grade 2 was 8.0 months in the cabozantinib group vs 6.4 months in the placebo group.

Study details: The data come from a randomized trial of 707 adults with HCC with albumin-bilirubin (ALBI) grades 1 or 2 at baseline who received 60 mg of cabozantinib daily or a placebo.

Disclosures: The study was supported by Exelixis. Lead author Dr. Kelley disclosed relationships with multiple companies including Exelixis.

Source: Kelley RK et al. Br J Cancer. 2021 Oct 7. doi: 10.1038/s41416-021-01532-5.